Capstone Therapeutics Corp. (OTCMKTS:CAPS) and its joint venture affiliate, LipimetiX Development, LLC holed a conference call and webcast to provide an operating update, discuss the start of AEM-28 Phase 1 clinical studies and report financial results for the fiscal year 2013. Capstone Therapeutics Corp. (OTCMKTS:CAPS) shares after opening at $0.27 moved to $0.28 on last trade day and at the end of the day closed at $0.260. Company price to sales ratio in past twelve months was calculated as -42.55 and price to cash ratio as -39.74. Capstone Therapeutics Corp. (OTCMKTS:CAPS) showed a positive weekly performance of 4.00%.
Xencor, Inc. (NASDAQ:XNCR) a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today presented an overview of its bispecific antibody programs at the Annual Summit on Practical and Emerging Trends in Multiple Myeloma being held in Whistler, British Columbia, Canada. Xencor Inc (NASDAQ:XNCR) shares fell -6.06% in last trading session and ended the day on $10.55. XNCR return on equity ratio is recorded as -105.90% and its return on assets is 621.10%.
Stock analysts at JMP Securities increased their price objective on shares of Durata Therapeutics (NASDAQ:DRTX) from $14.00 to $18.00 in a report issued on Tuesday,StockRatingsNetwork reports. The firm currently has an “outperform” rating on the stock. Durata Therapeutics Inc (NASDAQ:DRTX) shares moved down -5.33% in last trading session and was closed at $13.50 while trading in range of $13.39 – $14.83 – Durata Therapeutics Inc (NASDAQ:DRTX) year to date (YTD) performance is 5.55%.
Clovis Oncology Inc (NASDAQ:CLVS) reported Thursday from a conference in Geneva, Switzerland, that its orally delivered drug, CO-1686, is providing benefits to patients suffering from lung cancer and is being well-tolerated as doses are increased. Clovis Oncology Inc (NASDAQ:CLVS) weekly performance is -11.99%. On last trading day company shares ended up $70.33. Clovis Oncology Inc (NASDAQ:CLVS) distance from 50-day simple moving average (SMA50) is -5.92%. Analysts mean target price for the company is $101.17.